Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma

Palumbo, 2011, Multiple myeloma, N. Engl. J. Med., 364, 1046, 10.1056/NEJMra1011442

Guse, 2011, Oncolytic vaccinia virus for the treatment of cancer, Expert Opin. Biol. Ther., 11, 595, 10.1517/14712598.2011.558838

Heo, 2013, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat. Med., 19, 329, 10.1038/nm.3089

Parato, 2012, The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers, Mol. Ther., 20, 749, 10.1038/mt.2011.276

Deng, 2008, Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus, Leukemia, 22, 2261, 10.1038/leu.2008.120

Saito, 2009, Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8, JAMA, 301, 1025, 10.1001/jama.2009.289

Kidokoro, 2014, Vaccinia virus LC16m8Δ as a vaccine vector for clinical applications, Vaccines (Basel), 2, 755, 10.3390/vaccines2040755

Takahashi-Nishimaki, 1991, Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins, Virology, 181, 158, 10.1016/0042-6822(91)90480-Y

Hollinshead, 2001, Vaccinia virus utilizes microtubules for movement to the cell surface, J. Cell Biol., 154, 389, 10.1083/jcb.200104124

Kelly, 2008, Engineering microRNA responsiveness to decrease virus pathogenicity, Nat. Med., 14, 1278, 10.1038/nm.1776

Hikichi, 2011, MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy, Mol. Ther., 19, 1107, 10.1038/mt.2011.36

Buller, 1985, Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype, Nature, 317, 813, 10.1038/317813a0

Puhlmann, 2000, Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant, Cancer Gene Ther., 7, 66, 10.1038/sj.cgt.7700075

Casey, 2005, Adverse events associated with smallpox vaccination in the United States, January-October 2003, JAMA, 294, 2734, 10.1001/jama.294.21.2734

Lun, 2009, Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide, Clin. Cancer Res., 15, 2777, 10.1158/1078-0432.CCR-08-2342

Corthals, 2011, MicroRNA signatures characterize multiple myeloma patients, Leukemia, 25, 1784, 10.1038/leu.2011.147

Hsiao, 1998, Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain, J. Virol., 72, 8374, 10.1128/JVI.72.10.8374-8379.1998

Laliberte, 2009, Appraising the apoptotic mimicry model and the role of phospholipids for poxvirus entry, Proc. Natl. Acad. Sci. USA, 106, 17517, 10.1073/pnas.0909376106

de Magalhães, 2001, A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication, J. Biol. Chem., 276, 38353, 10.1074/jbc.M100183200

Andrade, 2004, The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication, Biochem. J., 381, 437, 10.1042/BJ20031375

Agirre, 2008, Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth, Mol. Cancer Res., 6, 1830, 10.1158/1541-7786.MCR-08-0167

Handa, 2012, Association between micro-RNA and epigenetic modifiers DNA methyltransferases (DNMTs), histone deacetylases (HDACs) in multiple myeloma (MM) and monoclonal gammmopathy with undetermined significance (MGUS), Blood, 120, 3942, 10.1182/blood.V120.21.3942.3942

Thomson, 2006, Extensive post-transcriptional regulation of microRNAs and its implications for cancer, Genes Dev., 20, 2202, 10.1101/gad.1444406

Nair, 2012, Clinical outcome prediction by microRNAs in human cancer: a systematic review, J. Natl. Cancer Inst., 104, 528, 10.1093/jnci/djs027

Johnson, 2005, RAS is regulated by the let-7 microRNA family, Cell, 120, 635, 10.1016/j.cell.2005.01.014

Hashizume, 1985

Bosma, 1983, A severe combined immunodeficiency mutation in the mouse, Nature, 301, 527, 10.1038/301527a0

Okazaki, 1988, Aberrant immunoglobulin gene rearrangement in scid mouse bone marrow cells, J. Immunol., 141, 1348, 10.4049/jimmunol.141.4.1348

Aloj, 2012, Severe combined immunodeficiences: new and old scenarios, Int. Rev. Immunol., 31, 43, 10.3109/08830185.2011.644607

Odunsi, 2012, Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients, Proc. Natl. Acad. Sci. USA, 109, 5797, 10.1073/pnas.1117208109

Amato, 2012, Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer, Future Oncol., 8, 231, 10.2217/fon.12.7

Walker, 2008, The immunostimulatory power of acute viral infection, Immunity, 28, 604, 10.1016/j.immuni.2008.04.009

Pütz, 2006, Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination, Nat. Med., 12, 1310, 10.1038/nm1457

Smith, 1983, Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA, Gene, 25, 21, 10.1016/0378-1119(83)90163-4

Bai, 2003, Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector, Gene Ther., 10, 1446, 10.1038/sj.gt.3302026